Stock NBRVF NABRIVA THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Nabriva Therapeutics plc

Equities

NBRVF

IE000OZRGNV6

Market Closed - OTC Markets
Other stock markets
 14:33:08 03/05/2024 BST 		5-day change 1st Jan Change
0.0001 USD 0.00% Intraday chart for Nabriva Therapeutics plc 0.00% +9,900.00%
2023 Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
2023 Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sumitomo Pharma Co., Ltd. acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.
Arbutus Biopharma Promotes Dr. Karen Sims to Chief Medical Officer, Hires Christopher Naftzger as Chief Compliance Officer
Nabriva Therapeutics plc Appoints H. Michael Hogan as Chief Executive Officer
Nabriva Therapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2023
Nabriva Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2022
Nabriva Therapeutics plc Auditor Raises 'Going Concern' Doubt
Merck : fin de l'accord de distribution avec Nabriva
Nabriva Therapeutics plc Appoints Christopher Naftzger as Interim Chief Executive Officer
Sector Update: Healthcare Stocks Rise Friday, Mostly Trail Other Sectors
Top Midday Decliners
Sector Update: Health Care Stocks Posting Moderate Advance Friday Afternoon
Sector Update: Health Care Stocks Gain Premarket Friday
December Jobs Report Showing Easing Wage Pressures Lift US Equity Futures
Nabriva Therapeutics Approves Wind-Down Plan, Will Terminate All Non-Essential Employees; Shares Fall Pre-Bell
Top Premarket Decliners
Nabriva Says Phase 1 Trial of Cystic Fibrosis Drug Candidate Shows Safety Profile in Line With Prior Studies in Healthy Subjects
Nabriva Therapeutics plc Announces Positive Topline Results from Phase 1 Trial of XENLETA in Adult Patients with Cystic Fibrosis
Nabriva Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Nabriva Therapeutics Completes Patient Enrollment for Phase 1 Trial of Potential Cystic Fibrosis Drug
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NBRVF Stock
  4. News Nabriva Therapeutics plc
  5. Other languages